These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 7811043)

  • 1. Effect of bismuth subsalicylate on ciprofloxacin bioavailability.
    Rambout L; Sahai J; Gallicano K; Oliveras L; Garber G
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2187-90. PubMed ID: 7811043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of subsalicylate bismuth on absorption of doxycycline.
    Ericsson CD; Feldman S; Pickering LK; Cleary TG
    JAMA; 1982 Apr; 247(16):2266-7. PubMed ID: 7040708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced tetracycline bioavailability caused by magnesium aluminum silicate in liquid formulations of bismuth subsalicylate.
    Healy DP; Dansereau RJ; Dunn AB; Clendening CE; Mounts AW; Deepe GS
    Ann Pharmacother; 1997 Dec; 31(12):1460-4. PubMed ID: 9416381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of bismuth subsalicylate with fruit juices, ascorbic acid, and thiol-containing substrates to produce soluble bismuth products active against Clostridium difficile.
    Mahony DE; Woods A; Eelman MD; Burford N; Veldhuyzen van Zanten SJ
    Antimicrob Agents Chemother; 2005 Jan; 49(1):431-3. PubMed ID: 15616328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro bile acid adsorption by bismuth subsalicylate and montmorillonite.
    Kocoshis SA; Ghent CN; Gryboski JD
    Dig Dis Sci; 1984 Dec; 29(12):1148-52. PubMed ID: 6499633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased tetracycline bioavailability caused by a bismuth subsalicylate antidiarrheal mixture.
    Albert KS; Welch RD; DeSante KA; DiSanto AR
    J Pharm Sci; 1979 May; 68(5):586-8. PubMed ID: 435335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence that bismuth salts reduce invasion of epithelial cells by enteroinvasive bacteria.
    Gump DW; Nadeau OW; Hendricks GM; Meyer DH
    Med Microbiol Immunol; 1992; 181(3):131-43. PubMed ID: 1522823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology of bismuth-containing compounds.
    Lambert JR
    Rev Infect Dis; 1991; 13 Suppl 8():S691-5. PubMed ID: 1925310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bismuth subsalicylate markedly decreases hydrogen sulfide release in the human colon.
    Suarez FL; Furne JK; Springfield J; Levitt MD
    Gastroenterology; 1998 May; 114(5):923-9. PubMed ID: 9558280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoprotective effect of bismuth subsalicylate in indomethacin-treated rats is associated with enhanced mucus bismuth concentration.
    Tanaka S; Guth PH; Carryl OR; Kaunitz JD
    Aliment Pharmacol Ther; 1997 Jun; 11(3):605-12. PubMed ID: 9218090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absorption of salicylate and bismuth from a bismuth subsalicylate--containing compound (Pepto-Bismol).
    Pickering LK; Feldman S; Ericsson CD; Cleary TG
    J Pediatr; 1981 Oct; 99(4):654-6. PubMed ID: 7277115
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of Bismuth Subsalicylate on Gastrointestinal Tolerability in Healthy Volunteers Receiving Oral Delayed-release Dimethyl Fumarate: PREVENT, a Randomized, Multicenter, Double-blind, Placebo-controlled Study.
    Koulinska I; Riester K; Chalkias S; Edwards MR
    Clin Ther; 2018 Dec; 40(12):2021-2030.e1. PubMed ID: 30447891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salicylate absorption from a bismuth subsalicylate preparation.
    Feldman S; Chen SL; Pickering LK; Cleary TG; Ericsson CD; Hulse M
    Clin Pharmacol Ther; 1981 Jun; 29(6):788-92. PubMed ID: 7226711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bismuth subsalicylate: history, chemistry, and safety.
    Bierer DW
    Rev Infect Dis; 1990; 12 Suppl 1():S3-8. PubMed ID: 2406853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Site of bismuth absorption from bismuth subsalicylate: implications for treatment of colonic conditions.
    Suarez FL; Furne J; Stiehm J; Garten C; Levitt MD
    Dig Dis Sci; 2000 Jul; 45(7):1444-6. PubMed ID: 10961727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of effects of ethyl alcohol and bismuth subsalicylate on gastric mucosal barrier in man.
    Dy RM; Lof J; DiBaise JK; Quigley EM
    Dig Dis Sci; 1999 Feb; 44(2):286-9. PubMed ID: 10063913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of bismuth salts on systemic and mucosal immune responses to orally administered cholera toxin.
    Horowitz NS; Staats HF; Palker TJ
    Immunopharmacology; 1995 Nov; 31(1):31-41. PubMed ID: 8655289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro synergy testing of clarithromycin and 14-hydroxyclarithromycin with amoxicillin or bismuth subsalicylate against Helicobacter pylori.
    Meyer JM; Ryu S; Pendland SL; Danziger LH
    Antimicrob Agents Chemother; 1997 Jul; 41(7):1607-8. PubMed ID: 9210696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of aluminum hydroxide/magnesium hydroxide antacid and bismuth subsalicylate on gastric pH in horses.
    Clark CK; Merritt AM; Burrow JA; Steible CK
    J Am Vet Med Assoc; 1996 May; 208(10):1687-91. PubMed ID: 8641951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of one-day oral dosing with three bismuth compounds for the suppression of Helicobacter pylori assessed by the 13C-urea breath test.
    Prewett EJ; Luk YW; Fraser AG; Lam WM; Pounder RE
    Aliment Pharmacol Ther; 1992 Feb; 6(1):97-102. PubMed ID: 1543820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.